

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
15 July 2021 (15.07.2021)



(10) International Publication Number  
**WO 2021/140143 A1**

(51) International Patent Classification:

C12N 9/10 (2006.01) C12R 1/90 (2006.01)  
C12N 15/79 (2006.01) C12P 21/00 (2006.01)

Published:

— with international search report (Art. 21(3))  
— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/050172

(22) International Filing Date:

07 January 2021 (07.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/958,070 07 January 2020 (07.01.2020) US

(71) Applicant: **LIMMATECH BIOLOGICS AG** [CH/CH];  
Grabenstr. 3, 8952 Schlieren (CH).

(72) Inventors: **MALLY, Manuela**; c/o LimmaTech Biologics AG Grabenstr. 3, 8952 Schlieren (CH). **FARIDMOAYER, Amirreza**; c/o LimmaTech Biologics AG Grabenstr. 3, 8952 Schlieren (CH). **FOLLADOR, Rainer**; c/o LimmaTech Biologics AG Grabenstr. 3, 8952 Schlieren (CH). **HARSMAN, Anke, Judith**; c/o LimmaTech Biologics AG Grabenstr. 3, 8952 Schlieren (CH).

(74) Agent: **JONES DAY LAW FIRM**; Prinzregentenstr. 11, 80538 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: GLYCOENGINEERING USING LEISHMANIA CELLS

(57) Abstract: The present application relates to *Leishmania* cells genetically engineered such that the formation of an O-linked GlcNAc on a polypeptide in the *Leishmania* cell is reduced or eliminated. The formation of the O-linked GlcNAc may be catalyzed in the *Leishmania* cell prior to said genetic engineering by at least one N-acetylglucosamine (GlcNAc)-transferase. Also provided herein are methods of making a polypeptide using a *Leishmania* cell described herein and polypeptides produced by the methods provided herein.

WO 2021/140143 A1